Navigation Links
McGill team discovers a piece of the puzzle for individualized cancer therapy via gene silencing
Date:5/26/2010

This press release is available in French.

In a major cancer-research breakthrough, researchers at the McGill University, Department of Biochemistry have discovered that a small segment of a protein that interacts with RNA can control the normal expression of genes including those that are active in cancer.

The research, published online on May 26, 2010 by the prestigious journal Nature, has important immediate applications for laboratory research and is another step toward the kind of individualized cancer therapies researchers are pursuing vigorously around the world.

Human cells need to produce the correct proteins at the right time and in the appropriate quantities to stay healthy. One of the key means by which cells achieve this control is by "RNA interference", a form of gene silencing where small pieces of RNA, called micro RNAs, obstruct the production of specific proteins by interacting with their genetic code. However, not any piece of RNA can do this. Dr. Bhushan Nagar and graduate student Filipp Frank, in collaboration with Dr. Nahum Sonenberg at McGill's new Life Sciences Complex, used structural biology to unravel how a small segment in the Argonaute proteins, the key molecules of RNA interference, can select the correct micro RNAs.

In doing so, the team has discovered that Argonaute proteins can potentially be exploited to enhance gene silencing. "RNA interference could be used as a viable therapeutic approach for inhibiting specific genes that are aberrantly active in diseases such as cancer", Nagar said. "We now have a handle on being able to rationally modify micro RNAs to make them more efficient and possibly into therapeutic drugs."

While therapeutic applications are many years away, this new insight provides an avenue to specifically control the production of proteins, which in cancer cells for example, are abnormal.

"This is fantastic news," said Dr. David Thomas, Chair of McGill's Department of Biochemistry. "You've seen stories lately about how we may see the end of chemotherapy? Well, this is part of that path in developing genetically based therapies that can be tailored to individual patients' particular illnesses. It's a great step forward."


'/>"/>

Contact: William Raillant-Clark
william.raillant-clark@mcgill.ca
514-398-2189
McGill University
Source:Eurekalert

Related biology news :

1. A study by the MUHC and McGill University opens a new door to understanding cancer
2. 12 McGill researchers awarded Canada Research Chairs
3. Type 1 diabetes triggered by lazy regulatory T-cells: McGill researchers
4. Tiny genetic differences have huge consequences: McGill researchers
5. Oceanographer Dennis J. McGillicuddy, Jr. receives 34th annual Rosenstiel Award
6. McGill conference on Global Food Crisis draws impressive list of international participants
7. Boost from McGill, Gates Foundation helps Africans control pharma research
8. Key to curing obesity may lie in worms that destroy their own fat: McGill researchers
9. MUHC and McGill scientists explain genetic disease first discovered in Quebec 24 years ago
10. Forget the antioxidants? McGill researchers cast doubt on role of free radicals in aging
11. Peptides-on-demand: McGill researchers radical new green chemistry makes the impossible possible
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology: